Aclaris Therapeut…
USUSDAclaris Therapeutics Inc (US:ACRS) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.
À propos de l'entreprise
- Site Web
- aclaristx.com
- Relations avec les Investisseurs
- investor.aclaristx.com/
- Secteur
- Health Care · Biotechnology: Pharmaceutical Preparations
- Siège Social
- WAYNE, United States
- PDG
- Neal S. Walker
- Employés
- 69
- Actions en Circulation
- 147.2 M au 2026-07-31
- Flottant
- 101.17 M
- Capitalisation Boursière
- 563.77 M USD
- Initiés
- 2.18%
- Investisseurs Institutionnels
- 84%
- Secteur d'Activité (SIC)
- Pharmaceutical Preparations
- FCF
- −62.2 M USD
- Dette
- 10.7 M USDtrésorerie nette
- Résultats et FCF — pour les 12 mois à 30.06.2026 (dernier rapport de l'entreprise).
Description
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Principaux Actionnaires
| Détenteur | Participation | Actions | Date du Rapport |
|---|---|---|---|
| RA Capital Management, L… | 9.1% | 12.72 M | 2026-06-30 |
| BML Capital Management,… | 8.56% | 11.98 M | 2026-06-30 |
| Blackrock Inc. | 7.18% | 10.04 M | 2026-06-30 |
| Deep Track Capital, Lp | 6.68% | 9.35 M | 2026-06-30 |
| Vivo Capital, LLC | 4.79% | 6.69 M | 2026-06-30 |
| Vanguard Capital Managem… | 4.16% | 5.82 M | 2026-06-30 |
| Frazier Life Sciences Ma… | 3.52% | 4.93 M | 2026-06-30 |
| Rock Springs Capital Man… | 3.1% | 4.33 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.03% | 4.24 M | 2026-06-30 |
| Adage Capital Partners G… | 2.91% | 4.07 M | 2026-06-30 |
| Decheng Capital LLC | 2.89% | 4.04 M | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.18% | 3.05 M | 2026-08-31 |
| Fidelity Advisor Series… | 1.27% | 1.78 M | 2026-08-31 |
| WALKER NEAL (Chief Execu… | ≈1.1% | 1.54 M | 2026-02-03 |
| VANGUARD INDEX FUNDS-Van… | 1.04% | 1.45 M | 2026-06-30 |
| Fidelity Salem Street Tr… | 0.93% | 1.3 M | 2026-07-31 |
| SPDR SERIES TRUST-State… | 0.71% | 986 220 | 2026-08-31 |
| iShares Trust-iShares Ru… | 0.69% | 968 147 | 2026-08-31 |
| Fidelity Covington Trust… | 0.6% | 834 440 | 2026-09-30 |
| iShares Trust-iShares Bi… | 0.59% | 822 091 | 2026-08-31 |
| Fidelity Select Portfoli… | 0.55% | 774 718 | 2026-08-31 |
| MEHRA ANAND M.D. (Direct… | ≈0.52% | 726 403 | 2026-06-05 |
| Fidelity Concord Street… | 0.44% | 621 941 | 2026-07-31 |
| VANGUARD SCOTTSDALE FUND… | 0.34% | 472 249 | 2026-05-31 |
| SCHIFF ANDREW N (Directo… | ≈0.33% | 459 995 | 2026-06-05 |
| MONAHAN JOSEPH B (Office… | ≈0.19% | 265 855 | 2025-02-28 |
| LOEROP JAMES (Officer) | ≈0.14% | 192 260 | 2026-02-03 |
| BALTHASER KEVIN J (Chief… | ≈0.13% | 187 453 | 2026-02-27 |
| MOLINEAUX CHRISTOPHER P… | ≈0.05% | 69 536 | 2026-06-05 |
| DAVIS HUGH M. (President… | ≈0.03% | 45 425 | 2026-02-03 |
| HUMPHRIES WILLIAM DOUGLA… | ≈0.03% | 45 105 | 2026-06-05 |
| LEONARD BRADEN MICHAEL (… | — | — | 2026-04-23 |
